Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Duke University Hospital · Duke Medical Center · +35 more institutions
Indexed incrossrefdatacitepubmed
Abstract
Background
Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation.
Methods
In this multinational, double-blind, randomized trial, we compared vorapaxar with placebo in 12,944 patients who had acute coronary syndromes without ST-segment elevation. The primary end point was a composite of death from cardiovascular causes, myocardial infarction, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization.
Citation impact
753
total citations
- FWCI
- 51.87
- Percentile
- 100%
- References
- 29
Citations per year
Authors
42Topics & keywords
Topics
Keywords
- Thrombin
- Antagonist
- Cardiology
- Medicine
- Internal medicine
- Receptor antagonist
- Receptor
- Pharmacology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.